Get a free sample of Ovarian Cancer Treatment Drugs Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Ovarian Cancer Treatment Drugs Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Ovarian Cancer Treatment Drugs Market Size
Ovarian Cancer Treatment Drugs Market was valued at USD 3.5 billion in 2023 and is expected to reach USD 6.1 billion by 2032, growing at a CAGR of 6.3% over the analysis period. High incidence of ovarian cancer is a major driver for market growth. According to the World Cancer Research Fund International (WCRF), ovarian cancer ranks eighth most commonly occurring cancer in women, causing more deaths annually than any other gynecological cancer. Similarly, as per Globocan’s 2020 projections, by 2040, the number of women around the world diagnosed with ovarian cancer will rise by almost 42% to 445,721 cases. Also, the number of women dying from ovarian cancer each year is projected to increase to 313,617, an increase of over 50% from 2020. Thus, growing cases of ovarian cancer will increase the demand for treatment, thereby fostering the market growth.
Ovarian cancer treatment drugs refer to pharmaceutical agents designed to prevent and manage ovarian cancer. These drugs are developed to target and impede the growth of cancer cells, either by directly attacking them or by inhibiting specific biological processes essential for their proliferation. Ovarian cancer treatment drugs include chemotherapy agents, targeted therapies, hormone therapies, and immunotherapies, among others.
How big is the North America ovarian cancer treatment drugs market?
North America industry for ovarian cancer treatment drugs held a sizable revenue share in 2023 and is projected to record robust growth through 2032 attributed to the growing number of patients with ovarian cancer across the region.
Why is the demand for targeted therapy ovarian cancer treatment drugs gaining traction?
The targeted therapy drugs segment accounted for 43.7% revenue share of the ovarian cancer treatment drugs industry in 2023 and is projected to record substantial growth through 2032 owing to the benefits identifying and combating cancer cells precisely and minimizing harm to healthy cells.
What is the size of the ovarian cancer treatment drugs market?
Industry size for ovarian cancer treatment drugs reached USD 3.5 billion in 2023 and is projected to be worth USD 6.1 billion by 2032 driven by the high incidence of ovarian cancer globally.
Which are the major ovarian cancer treatment dug companies?
Some of the top ovarian cancer treatment drugs industry players are F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., Astrazeneca, Merck KGaA, Oasmia Pharmaceutical AB, Clovis Oncology, Inc., Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., and Allarity Therapeutics, among others.